NEMERA in the news
design, manufacturing, medical devices
Tamtam found 20 recent articles about NEMERA.
- SCHOTT Pharma and Nemera launch first fully compatible large-volume passive safety system
SCHOTT Pharma and Nemera introduced the first fully compatible large-volume passive safety system with a 5.5 ml prefillable glass syringe, designed for safe and user-friendly self-administration of large-volume biologics.
- Nouvelle usine en Seine-Maritime : « Nemera refuse de subir la désindustrialisation ! »
Nemera, a drug delivery device company, inaugurated a new 30 million euro factory in Seine-Maritime, France, expected to be operational by February 2027.
- Nemera inaugure son nouveau site de production, à quelques kilomètres de son usine historique du Tréport
Nemera has opened a new production facility in Ponts-et-Marais to expand its manufacturing of drug delivery devices and support its rapid growth.
- Le groupe Nemera inaugure une usine flambant neuve près des Villes sœurs
Nemera celebrated the grand opening of its new drug delivery device manufacturing plant near the Sister Cities.
- Nemera en vente : le private equity teste le prix de l'obésité
Astorg and Montagu are exploring the sale of Nemera, a French manufacturer of injector pens for obesity drugs, aiming for a 3 billion euro valuation.
- Nemera DuoSpray : administration nasale sans aiguille pour thérapies systémiques - Actualités et statistiques
Nemera launched DuoSpray, a new needle-free nasal spray platform for quick systemic drug delivery with self-administration.
- Nemera launches bi-dose nasal spray solution
Nemera introduces DuoSpray, a new bi-dose nasal spray platform for systemic nasal therapies that enables rapid action and self-administration.
- Nemera launches bi-dose nasal spray solution
Nemera has introduced DuoSpray, a new bi-dose nasal spray platform for needle-free, self-administered systemic nasal therapies.
- Private Equity Eyes Sale of GLP-1 Device Maker Nemera
Astorg and Montagu are looking to sell Nemera, a French provider of drug delivery systems for GLP-1 therapies, amidst high demand for weight-loss medications.
- Nemera owners explore sale after GLP-1 device demand surge - Bloomberg
Nemera's private equity owners are exploring a sale of the drug delivery device manufacturer, potentially valuing it at €3 billion, driven by surging demand for GLP-1 medication devices.
- The owners of Nemera intend to sell a controlling stake
Nemera's owners are exploring the sale of a controlling stake in the company, valued at 3 billion euros, as Nemera plans to expand production of medical devices for weight loss drugs.
- Nemera owners explore sale after GLP-1 device demand surge - Bloomberg
Nemera's private equity owners are exploring a sale of the drug delivery device manufacturer, potentially valuing it at €3 billion, driven by surging demand for GLP-1 weight loss drug devices.
- Private Equity Firms Consider Divesting Nemera, Maker of GLP-1 Injection Devices
Astorg and Montagu are exploring the sale of Nemera, a medical device company specializing in GLP-1 injection systems, valued at approximately •3 billion due to the growing weight-loss drug market.
- Nemera owners explore sale after GLP-1 device demand surge - Bloomberg
Nemera's private equity owners are exploring a sale of the drug delivery device manufacturer for an estimated €3 billion following a surge in demand for GLP-1 medication devices.
- Astorg, Montagu Said to Eye Sale of GLP-1 Pen Maker Nemera
Nemera's private equity owners are exploring a sale of the company, which produces drug delivery devices, for an estimated €3 billion.
- Les propriétaires de Nemera explorent une vente après la hausse de la demande de dispositifs GLP-1
Nemera's private equity owners are exploring a sale of the drug delivery device manufacturer, potentially valuing it at 3 billion euros, driven by rising demand for GLP-1 drug devices.
- Plus de 3 milliards en vue ? Astorg espère une sortie XXL grâce à Nemera
Nemera is a pharmaceutical device manufacturer whose potential sale is expected to exceed 3 billion euros.
- Nemera and SCHOTT Pharma deliver verified pen injector platform with sterile cartridge system
Nemera and SCHOTT Pharma partnered to provide pharmaceutical companies with a verified pen injector platform using a sterile cartridge system for patient-centric injectable therapies in homecare.
- Pen Injector Platform with Sterile Cartridge System From: SCHOTT Pharmaceutical Packaging
SCHOTT Pharma and Nemera partnered to provide a reliable, pre-verified pen injector platform with a sterile cartridge system for injectable therapies.
- Santé. Nemera muscle son outil industriel avec 33 M€ investis dans son nouveau site de Ponts-et-Marais
Nemera is investing €33 million in a new 3,000 m² industrial facility in Normandy to boost medical device production capacity by 2026.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like NEMERA?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies